glp-1 supply news today 2025 Pipeline Update: August - Prime Therapeutics GLP-1s in 2026: What Brokers

Liver X receptor agonist therapy prevents diffuse alveolar hemorrhage in murine lupus by repolarizing macrophages

95% CI: 0.52, 1.73

A synthetic version of part of this peptide, called TB-500, is marketed as an aid to repair tissue, reduce inflammation and improve flexibility

Description This encapsulated research formulation combines BPC-157 and TB-500 for experimental characterization of gastrointestinal stability, mucosal transport, and systemic biodistribution

Laboratory studies demonstrate that GLP-1 receptor agonists suppress macrophage secretion of multiple inflammatory cytokines including IFN-gamma, IL-17, IL-2, TNF-beta, IL-6, and IL-1beta